Do analysts rate PHG or LQDA?

Liquidia has a consensus price target of $68.88, suggesting a potential downside of 11.62%. Given Liquidia's stronger consensus rating and higher probable upside, analysts clearly believe Liquidia is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Liquidia 2 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 3 Strong Buy rating(s) 2.82

Which has higher valuation and earnings, PHG or LQDA?

Koninklijke Philips has higher revenue and earnings than Liquidia. Koninklijke Philips is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Koninklijke Philips $20.17B 1.34 $1.01B $1.17 23.42 Liquidia $158.32M 43.77 -$68.92M $0.14 556.64

Does the media favor PHG or LQDA?

In the previous week, Liquidia had 8 more articles in the media than Koninklijke Philips. MarketBeat recorded 10 mentions for Liquidia and 2 mentions for Koninklijke Philips. Liquidia's average media sentiment score of 0.59 beat Koninklijke Philips' score of 0.00 indicating that Liquidia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Liquidia 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, LQDA or ZBH?

Zimmer Biomet has higher revenue and earnings than Liquidia. Zimmer Biomet is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 43.77 -$68.92M $0.14 556.64 Zimmer Biomet $8.23B 2.15 $705.20M $3.85 23.77

Is LQDA or ZBH more profitable?

Zimmer Biomet has a net margin of 9.05% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Zimmer Biomet's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 7.74% 46.82% 7.06% Zimmer Biomet 9.05% 13.24% 7.28%

Does the media refer more to LQDA or ZBH?

In the previous week, Liquidia had 2 more articles in the media than Zimmer Biomet. MarketBeat recorded 10 mentions for Liquidia and 8 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 0.99 beat Liquidia's score of 0.59 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, SOLV or LQDA?

Solventum has higher revenue and earnings than Liquidia. Solventum is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.33B 1.60 $1.56B $8.16 9.40 Liquidia $158.32M 43.77 -$68.92M $0.14 556.64

Is SOLV or LQDA more profitable?

Solventum has a net margin of 17.33% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Solventum's return on equity. Company Net Margins Return on Equity Return on Assets Solventum 17.33% 23.51% 7.63% Liquidia 7.74% 46.82% 7.06%

Does the media prefer SOLV or LQDA?

In the previous week, Liquidia had 4 more articles in the media than Solventum. MarketBeat recorded 10 mentions for Liquidia and 6 mentions for Solventum. Solventum's average media sentiment score of 1.27 beat Liquidia's score of 0.59 indicating that Solventum is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, LQDA or SNN?

Smith & Nephew SNATS has higher revenue and earnings than Liquidia. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 43.77 -$68.92M $0.14 556.64 Smith & Nephew SNATS $6.16B 2.12 $625M N/A N/A

Does the media refer more to LQDA or SNN?

In the previous week, Liquidia had 7 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 10 mentions for Liquidia and 3 mentions for Smith & Nephew SNATS. Liquidia's average media sentiment score of 0.59 beat Smith & Nephew SNATS's score of 0.34 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, LQDA or PEN?

Penumbra has higher revenue and earnings than Liquidia. Penumbra is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 43.77 -$68.92M $0.14 556.64 Penumbra $1.45B 8.60 $177.69M $4.34 73.24

Is LQDA or PEN more profitable?

Penumbra has a net margin of 11.76% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 7.74% 46.82% 7.06% Penumbra 11.76% 10.87% 8.45%

Does the media refer more to LQDA or PEN?

In the previous week, Liquidia had 7 more articles in the media than Penumbra. MarketBeat recorded 10 mentions for Liquidia and 3 mentions for Penumbra. Liquidia's average media sentiment score of 0.59 beat Penumbra's score of 0.00 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Liquidia (LQDA) Competitors

$77.93 -3.52 (-4.32%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$78.67 +0.73 (+0.94%)

As of 07/10/2026 07:44 PM Eastern

Compare

LQDA vs. PHG, ZBH, SOLV, SNN, and PEN

Should you buy Liquidia stock or one of its competitors? MarketBeat compares Liquidia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Liquidia include Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), and Penumbra (PEN). These companies are all part of the "medical equipment" industry.

How does Liquidia compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Liquidia has a net margin of 7.74% compared to Koninklijke Philips' net margin of 5.49%. Liquidia's return on equity of 46.82% beat Koninklijke Philips' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	5.49%	13.51%	5.48%
Liquidia	7.74%	46.82%	7.06%

Liquidia has a consensus price target of $68.88, suggesting a potential downside of 11.62%. Given Liquidia's stronger consensus rating and higher probable upside, analysts clearly believe Liquidia is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82

In the previous week, Liquidia had 8 more articles in the media than Koninklijke Philips. MarketBeat recorded 10 mentions for Liquidia and 2 mentions for Koninklijke Philips. Liquidia's average media sentiment score of 0.59 beat Koninklijke Philips' score of 0.00 indicating that Liquidia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liquidia	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Koninklijke Philips has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

13.7% of Koninklijke Philips shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Koninklijke Philips has higher revenue and earnings than Liquidia. Koninklijke Philips is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.34	$1.01B	$1.17	23.42
Liquidia	$158.32M	43.77	-$68.92M	$0.14	556.64

Summary

Liquidia beats Koninklijke Philips on 13 of the 17 factors compared between the two stocks.

How does Liquidia compare to Zimmer Biomet?

Liquidia (NASDAQ:LQDA) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Zimmer Biomet has a net margin of 9.05% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
Zimmer Biomet	9.05%	13.24%	7.28%

In the previous week, Liquidia had 2 more articles in the media than Zimmer Biomet. MarketBeat recorded 10 mentions for Liquidia and 8 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 0.99 beat Liquidia's score of 0.59 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zimmer Biomet has higher revenue and earnings than Liquidia. Zimmer Biomet is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	43.77	-$68.92M	$0.14	556.64
Zimmer Biomet	$8.23B	2.15	$705.20M	$3.85	23.77

64.5% of Liquidia shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Liquidia has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Liquidia presently has a consensus price target of $68.88, suggesting a potential downside of 11.62%. Zimmer Biomet has a consensus price target of $102.33, suggesting a potential upside of 11.82%. Given Zimmer Biomet's higher possible upside, analysts clearly believe Zimmer Biomet is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82
Zimmer Biomet	3 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.25

Summary

Zimmer Biomet beats Liquidia on 9 of the 17 factors compared between the two stocks.

How does Liquidia compare to Solventum?

Solventum (NYSE:SOLV) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Solventum has higher revenue and earnings than Liquidia. Solventum is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.60	$1.56B	$8.16	9.40
Liquidia	$158.32M	43.77	-$68.92M	$0.14	556.64

Solventum has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

Solventum presently has a consensus price target of $83.50, indicating a potential upside of 8.83%. Liquidia has a consensus price target of $68.88, indicating a potential downside of 11.62%. Given Solventum's higher probable upside, analysts plainly believe Solventum is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82

64.5% of Liquidia shares are held by institutional investors. 0.2% of Solventum shares are held by insiders. Comparatively, 25.6% of Liquidia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Liquidia had 4 more articles in the media than Solventum. MarketBeat recorded 10 mentions for Liquidia and 6 mentions for Solventum. Solventum's average media sentiment score of 1.27 beat Liquidia's score of 0.59 indicating that Solventum is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has a net margin of 17.33% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Solventum's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Liquidia	7.74%	46.82%	7.06%

Summary

Solventum beats Liquidia on 9 of the 17 factors compared between the two stocks.

How does Liquidia compare to Smith & Nephew SNATS?

Liquidia (NASDAQ:LQDA) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Liquidia has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

64.5% of Liquidia shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Liquidia had 7 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 10 mentions for Liquidia and 3 mentions for Smith & Nephew SNATS. Liquidia's average media sentiment score of 0.59 beat Smith & Nephew SNATS's score of 0.34 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Liquidia has a net margin of 7.74% compared to Smith & Nephew SNATS's net margin of 0.00%. Liquidia's return on equity of 46.82% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
Smith & Nephew SNATS	N/A	N/A	N/A

Liquidia currently has a consensus price target of $68.88, suggesting a potential downside of 11.62%. Smith & Nephew SNATS has a consensus price target of $30.93, suggesting a potential upside of 0.78%. Given Smith & Nephew SNATS's higher possible upside, analysts plainly believe Smith & Nephew SNATS is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

Smith & Nephew SNATS has higher revenue and earnings than Liquidia.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	43.77	-$68.92M	$0.14	556.64
Smith & Nephew SNATS	$6.16B	2.12	$625M	N/A	N/A

Summary

Liquidia beats Smith & Nephew SNATS on 11 of the 15 factors compared between the two stocks.

How does Liquidia compare to Penumbra?

Liquidia (NASDAQ:LQDA) and Penumbra (NYSE:PEN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Penumbra has a net margin of 11.76% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
Penumbra	11.76%	10.87%	8.45%

Liquidia has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Penumbra has higher revenue and earnings than Liquidia. Penumbra is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	43.77	-$68.92M	$0.14	556.64
Penumbra	$1.45B	8.60	$177.69M	$4.34	73.24

Liquidia currently has a consensus target price of $68.88, indicating a potential downside of 11.62%. Penumbra has a consensus target price of $360.33, indicating a potential upside of 13.36%. Given Penumbra's higher possible upside, analysts plainly believe Penumbra is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82
Penumbra	1 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11

In the previous week, Liquidia had 7 more articles in the media than Penumbra. MarketBeat recorded 10 mentions for Liquidia and 3 mentions for Penumbra. Liquidia's average media sentiment score of 0.59 beat Penumbra's score of 0.00 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.5% of Liquidia shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 2.9% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Liquidia beats Penumbra on 9 of the 17 factors compared between the two stocks.

Get Liquidia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LQDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LQDA vs. The Competition

Export

Metric	Liquidia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.24B	$3.76B	$7.14B	$12.64B
Dividend Yield	N/A	2.17%	2.68%	7.83%
P/E Ratio	556.68	21.83	27.42	24.58
Price / Sales	43.77	323.85	593.42	121.62
Price / Cash	N/A	147.64	49.34	60.04
Price / Book	152.80	8.41	10.88	6.38
Net Income	-$68.92M	$23.85M	$3.59B	$331.87M
7 Day Performance	-1.27%	-0.75%	-0.26%	0.37%
1 Month Performance	8.80%	8.81%	4.52%	0.53%
1 Year Performance	453.09%	53.66%	29.17%	21.96%

Liquidia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LQDA Liquidia	2.7739 of 5 stars	$77.93 -4.3%	$68.88 -11.6%	+450.7%	$7.24B	$158.32M	556.68	50	Insider Trade
PHG Koninklijke Philips	2.1235 of 5 stars	$28.17 +1.6%	N/A	+11.2%	$27.27B	$20.17B	24.14	65,340
ZBH Zimmer Biomet	3.8342 of 5 stars	$89.75 +2.6%	$102.70 +14.4%	-3.8%	$16.92B	$8.23B	23.31	17,000	Analyst Upgrade Options Volume
SOLV Solventum	4.0271 of 5 stars	$77.87 -0.5%	$83.73 +7.5%	+1.1%	$13.55B	$8.33B	12.54	20,000	News Coverage Positive News Analyst Upgrade
SNN Smith & Nephew SNATS	2.1679 of 5 stars	$30.53 +0.9%	$30.93 +1.3%	-1.2%	$12.86B	$6.16B	N/A	16,988	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LQDA) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Liquidia (LQDA) Competitors

LQDA vs. PHG, ZBH, SOLV, SNN, and PEN

How does Liquidia compare to Koninklijke Philips?

Summary

How does Liquidia compare to Zimmer Biomet?

Summary

How does Liquidia compare to Solventum?

Summary

How does Liquidia compare to Smith & Nephew SNATS?

Summary

How does Liquidia compare to Penumbra?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA vs. The Competition

Liquidia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Liquidia (LQDA) Competitors

LQDA vs. PHG, ZBH, SOLV, SNN, and PEN

How does Liquidia compare to Koninklijke Philips?

Is PHG or LQDA more profitable?

Do analysts rate PHG or LQDA?

Does the media favor PHG or LQDA?

Which has more volatility and risk, PHG or LQDA?

Do institutionals and insiders believe in PHG or LQDA?

Which has higher valuation and earnings, PHG or LQDA?

Summary

How does Liquidia compare to Zimmer Biomet?

Is LQDA or ZBH more profitable?

Does the media refer more to LQDA or ZBH?

Which has stronger valuation & earnings, LQDA or ZBH?

Do institutionals & insiders hold more shares of LQDA or ZBH?

Which has more volatility and risk, LQDA or ZBH?

Do analysts prefer LQDA or ZBH?

Summary

How does Liquidia compare to Solventum?

Which has better earnings & valuation, SOLV or LQDA?

Which has more volatility & risk, SOLV or LQDA?

Do analysts rate SOLV or LQDA?

Do insiders and institutionals believe in SOLV or LQDA?

Does the media prefer SOLV or LQDA?

Is SOLV or LQDA more profitable?

Summary

How does Liquidia compare to Smith & Nephew SNATS?

Which has more volatility and risk, LQDA or SNN?

Do insiders & institutionals believe in LQDA or SNN?

Does the media refer more to LQDA or SNN?

Is LQDA or SNN more profitable?

Do analysts rate LQDA or SNN?

Which has better earnings & valuation, LQDA or SNN?

Summary

How does Liquidia compare to Penumbra?

Is LQDA or PEN more profitable?

Which has more risk & volatility, LQDA or PEN?

Which has higher valuation & earnings, LQDA or PEN?

Do analysts rate LQDA or PEN?

Does the media refer more to LQDA or PEN?

Do insiders and institutionals believe in LQDA or PEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA vs. The Competition

Liquidia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools